1

The tryptophan catabolite or kynurenine pathway in Alzheimer's disease: a

systematic review and meta-analysis.

SHORT TITLE: Kynurenine pathway in Alzheimer's disease

Abbas F. Almulla, Ph.D. a, Thitiporn Supasitthumrong, M.D. a, Arisara Amrapala, MS.ca,

Chavit Tunvirachaisakul, M.D., Ph.D.a, Al-Karrar Kais Abdul Jaleel, MS.cb, Gregory

Oxenkrug, M.D., Ph.D.^c, Hussein K. Al-Hakeim, Ph.D.^d, Michael Maes, M.D., Ph.D.^{a,e,f}

^a Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok,

Thailand.

^b Medical Laboratory Technology Department, College of Medical Technology, The

Islamic University, Najaf, Iraq.

^c Department of Psychiatry, Tufts University School of Medicine and Tufts Medical

Center, Boston, MA 02111, USA.

^d Department of Chemistry, College of Science, University of Kufa, Kufa, Iraq.

^e Department of Psychiatry, Medical University of Plovdiy, Plovdiy, Bulgaria.

f Department of Psychiatry, IMPACT Strategic Research Centre, Deakin University,

Geelong, Victoria, Australia.

Corresponding author:

Prof. Dr Michael Maes, M.D., Ph.D.

Department of Psychiatry

Faculty of Medicine, Chulalongkorn University

Bangkok, 10330

Thailand

Email: <u>Dr.michaelmaes@hotmail.com</u>

E-mail addresses:

Abbass.chem.almulla1991@gmail.com

Thitiporn.S@chula.ac.th

lily.amrapala@gmail.com

Chavit.tun@gmail.com

Alkkais50@gmail.com

goxenkrug@tuftsmedicalcenter.org

headm2010@yahoo.com

dr.michaelmaes@hotmail.com

ESF, Table 1: Search sentences and terms were used in each database

Database Name	Search Sentence	No. of
Database (vaine		Articles
	((((((((((((((((((((((((((((((((((((((
	OR (Alzheimer's disease and kynurenic acid)) OR (Alzheimer's disease and	
	quinolinic acid)) OR (Alzheimer's disease and Picolinic acid)) OR (Alzheimer's	
	disease and 3-hydroxyanthranilic acid)) OR (Alzheimer's disease and xanthurenic	
	acid)) OR (Alzheimer's disease and 3-hydroxykynurenine)) OR (Alzheimer's	707
	disease and Anthranilic acid)) OR (Alzheimer's disease and formyl kynurenine))	
	OR (Alzheimer's disease and l-tryptophan)) OR (Alzheimer's disease and	
	tryptophan catabolites)) OR (TRYCATs and Alzheimer's disease)) OR (TRYCATs	
	and AD)	
	((((((((((((((((((((((((((((((((((((((
DubMad/Madlina	impairment)) OR (TRYCAT pathway and Alzheimer's disease)) OR (Kynurenine	
PubMed/Medline	pathway and Alzheimer's disease)) OR (IDO and Alzheimer's disease)) OR	
	(kynurenine and dementia)) OR (kynurenic acid and dementia)) OR (3-	387
	Hydroxykynurenine and dementia)) OR (xanthurenic acid and dementia)) OR (3-	
	Hydroxyanthranilic acid and dementia)) OR (Quinolinic acid and dementia)) OR	
	(Picolinic acid and dementia)	
	((((((((((((((((((((((((((((((((((((((
	enzyme)) OR (Alzheimer's disease and KAT enzyme)) OR (Alzheimer's disease and	
	KMO enzyme)) OR (Alzheimer's disease and Kynureninase enzyme)) OR (SARS-	2055
	Dementia and IDO enzyme)) OR (Dementia and KAT enzyme)) OR (Dementia and	2075
	Kynurenine pathway)) OR (Dementia and Kynureninase enzyme)) OR (Dementia	
	and TDO)	
	((((((Alzheimer's disease* and IDO activation) OR (TDO activation)) OR	
	(Kynurenine pathway)) OR (KMO activation)) OR (Tryptophan degradation)) AND	3390
Google Scholar	(Decreased Tryptophan)	
	(((((Alzheimer's disease* and kynurenine pathway) OR (TRYCAT pathway)) OR	2220
	(Tryptophan)) OR (kynurenine)) OR (kynurenic acid)) AND (3-	aaa0

Hydroxykynurenine) OR (Xanthurenic acid)) OR (Quinolinic acid)) OR (Picolinic	
acid)) OR (Anthranilic acid)) OR (3-Hydroxyanthranilic acid))	
((((((((((((((((((((((((((((((((((((((
disease and Kynurenine pathway)) OR ALL=(Alzheimer's disease and	
kynurenine)) OR ALL=(Alzheimer's disease and kynurenic acid)) OR	
ALL=(Alzheimer's disease and 3-Hydroxykynurenine)) OR ALL=(Alzheimer's	630
disease and Xanthurenic acid)) OR ALL=(Alzheimer's disease and Anthranilic	030
acid)) OR ALL=(Alzheimer's disease and Quinolinic acid)) OR ALL=(Alzheimer's	
disease and 3-Hydroxyanthranilic acid)) OR ALL=(Alzheimer's disease and	
Picolinic acid)	
((((((((((((((((((((((((((((((((((((((
disease and KAT enzyme)) OR ALL=(Alzheimer's disease and KMO enzyme))	
OR ALL=(Alzheimer's disease and TDO enzyme)) OR ALL=(Alzheimer's disease	395
and Kynureninase enzyme)) OR ALL=(Dementia and kynurenine pathway)) OR	393
ALL=(Dementia and TRYCATs)) OR ALL=(Dementia and TRYCAT pathway))	
OR ALL=(Dementia and tryptophan)) OR ALL=(Dementia and kynurenine)	
Alzheimer's disease and kynurenine pathway, Alzheimer's disease and tryptophan	
catabolism pathway, Alzheimer's disease and TRYCATs, Alzheimer's disease and	70
kynurenine, Alzheimer's disease and tryptophan, Alzheimer's disease kynurenic	70
acid, Dementia and kynurenine pathway	
	acid)) OR (Anthranilic acid)) OR (3-Hydroxyanthranilic acid)) ((((((((((((((((((((((((((((((((((

EFS, Table 2: Studies excluded from the meta-analysis but included in the systematic review.

Authors, year	Reason why excluded from the meta-analysis
Porter, Lunn et al. 2003	The author did not show a quantitive data
Guillemin, Brew et al. 2005	No data for measured analytes were presented
Trushina, Dutta et al. 2013	No mean (SD) for measured analytes
Bonda, Mailankot et al. 2010	The article included antibody against TRYCATs
Porter, Lunn et al. 2003	No data for the baseline levels

ESF, Table 3. Immune cofounder's scale (ICS) applied from Andrés-Rodríguez, et al., 2019

Met	hodological quality of the study
1	Study sample ≥ 128 participants including patients and controls (1= Yes, 0 = No)
2	Did the study control the results for potential confounders (e.g., age, BMI, gender, race)? (1= Yes, 0 = No)
3	Were participants with schizophrenia and controls age- and-gender-matched or was there a statistical control? $(1= Yes, 0= No)$
4	Was the time of sample collection specified (e.g., morning vs. evening)? (1= Yes, 0 = No)
5	Were participants with Alzheimer disease free of immunomodulatory drugs including anti- cytokines, glucocorticoids, immunoglobulins, and immunosuppressants, or was there a medication washout period or was drug intake statistically controlled for? (1= Yes, 0 = No)
6	Were participants with schizophrenia free of nervous system drugs or were the data statistically controlled for? $(1=Yes, 0=No)$
7	Reporting either the manufacturer of the test or detection limit and coefficients of variation (1= Yes , $0 = No$)
8	Reporting how data under detection limit were handled (1 = Yes, 0 = No)
9	Reporting % of the sample under detection limit (1=Yes, 0= No)
10	Reporting blood fraction (serum, plasma, culture supernatant or whole blood) (1= Yes, 0 = No)
	Total quality score (10 points)
	narker confounders red points red points should not be given if the item is statistically controlled for
1	3 red points for comorbid illnesses such as autoimmune disorders & other immune disorders including rheumatoid arthritis, psoriasis, inflammatory bowel disease, chronic obstructive pulmonary disease, multiple sclerosis
2	3 red points for use of recreational drugs such as methamphetamine or opioids
3	2 red points when groups were not matched for age
4	2 red points when groups were not matched for sex

5	2 red points for medication use as for example immunomodulators	
6	2 red points for early traumatic life events	
7	2 red points for shift work and primary sleep disorders	
8	1.5 red points for use of neuroleptics	
9	1 red point for more common systemic immune disorders including diabetes type 1/2, essential hypertension, metabolic syndrome	
10	1 red point for not fasting (8 hours before blood extraction)	
11	1 red point for use of omega-3 and antioxidant supplements	
12	1 red point when data were not controlled for body mass index	
13	1 red point when data were not controlled for physical activity or sedentary life	
14	1 red point when data were not controlled for smoking	
15	1 red point for use of oral contraceptives or NSAIDs	
16	0.5 red points when data were not controlled for ethnicity in countries such as US, Brazil	
17	0.5 red points when data were not controlled for seasonality	
18	0.5 red points when data were not controlled for diurnal variation (8-10 a.m. versus all other time points)	
	Total red point score (26 points)	

ESF, Table 4. PRISMA checklist

Section/topic # Checklist item			Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3	
INTRODUCTIO	ON		
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	9
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	10
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	11
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	11
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	11
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	11
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	11
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	11
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this	12

_	1		1
		was done at the study or outcome level), and how this information is to be used in any data synthesis.	
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	12
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	12
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	13
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	14
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	15
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	15
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	ESF, 8, table 6
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	ESF, 7, table 5
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	45, table 2
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	ESF, 8, table 6
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	ESF, 9, table 7
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	21-25
Limitations	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).		
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	26, Figure 6
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the	27

	systematic review.	
	Systematic Teview.	

ESF, Table 5: Characteristics of Studies which included in the systematic reviews and meta-analysis

NO	Authors, years	Setting	Type of	Type of	Sa	ample Size		Ag	e	Assessed	Specimen	Method	Quality score	Red point	Findnigs in AD patients compared
100	Authors, years	Setting	case	Control	Cases (M/F)	Control M/F	Total M/F	Case-Mean (SD)	Control- Mean(SD)	Biomarkers	Бресписи	Method		score	to HC
1	Oxenkrug, van der Hart et al. 2017	USA	AD	НС	20 (12/8)	24 (12/12)	44 (24/20)	-	-	3HK,AA,KA,K YN,TRP,XA	Plasma	HPLC- MS	4	13.5	Low TRP, AA,KA High KYN,3HK, XA
2	Giil, Midttun et al. 2017	Norway	AD	НС	65 (37/28)	65 (32/33)	130 (69/51)	74,3(15,1)	81,6(8,6)	3HK, AA, KA,KYN, QA, TRP, XA	Plasma	LC- MS/MS	6	12,5	Low TRP, KYN, 3HK, KA, XA, AA, QA
3	Rommer, Fuchs et al. 2016	Austria	AD	НС	16 (7/9)	15 (4/11)	31 (11/20)	63,3(13,7)	62,8(3,6)	TRP, KYN	Serum	LC	7,5	12	Low TRP High KYN
4	Wennstrom, Nielsen et al. 2014	Sweden	AD	НС	19 (9/10)	20 (10/10)	39 (10/20)	75,3(5,6)	77(10,3)	KA	CSF	HPLC	4,5	11	Low KA
5	Schwarz, Guillemin et al. 2013	Germany	AD	НС	20 (4/16)	19 (11/8)	39 (15/24)	74(7,6)	59,5(10,2)	3HK, KA, KYN, QA, TRP	Serum	HPLC	5,5	12,5	Low TRP, KA, QA High KYN, 3HK, PA
6	Gulaj, Pawlak et al. 2010	Poland	AD	НС	34 (10/24)	18 (5/13)	52 (15/37)	78,8(5,6)	76,1(7,3)	3HK, AA, KA, KYN, QA, TRP	Plasma	HPLC	8	10,5	Low (TRP, 3HK,AA,KA) High (QA,KYN)
7	Greilberger, Fuchs et al. 2010	Austria	AD	НС	16 (7/9)	15 (4/11)	31 (11/20)	63,3(13,7)	62,8(3,6)	TRP, KYN	Serum	HPLC	4,5	10	Low TRP High KYN
8	Hartai, Juhasz et al. 2007	Hungary	AD	НС	28 (6/22)	31 (10/21)	59 (16/43)	77(6.3)	73(8.3)	KYN, KA	Plasma	HPLC	4,5	11	Low KA, KYN
9	Widner, Leblhuber et al. 2000	Austria	AD	НС	21 (6/15)	20 (10/10)	41 (16/25)	74,4(5,4)	73,4(7,4)	TRP, KYN	Serum	HPLC	5	10	Low TRP High KYN
10	Baran, Jellinger et al. 1999	Austria	AD	НС	11 (2/9)	13 (7/6)	24 (9/15)	81(6,3)	80,1(7,9)	3HK, KA, KYN,	Brain tissue	HPLC	5	11	Low KYN, 3HK High KA
11	Bonaccorso, Lin et al. 1998	Belgium	AD	НС	15 (3/12)	31 (14/17)	46 (17/29)	78,4(10,3)	55,2(22,2)	TRP	Plasma	HPLC	5,5	10	Low TRP
12	Tohgi, Abe et al. 1995	Japan	AD	НС	15	10	25	68(6)	69(6)	TRP, KYN, 3HK	CSF	HPLC	5,5	10	Low TRP, KYN, 3HK
13	Tohgi, Abe et al. 1992	Japan	AD	НС	14	10	24	68,4(10,1)	68,5(6,1)	TRP, KYN, 3HK	CSF	HPLC	5,5	10	Low TRP, KYN, 3HK
14	Willette, Pappas et al. 2021	USA	AD	НС	112 (65/47)	58 (30/28)	170 (95/75)	74,8(8)	75,1(5,7)	TRP, KYN	Serum	LC-MS	9	10,5	High TRP Low KYN
15	Whiley, Chappell et al. 2021	UK	AD	CN	103 (50/53)	86 (44/42)	189 (94/95)	76,9(5,8)	75,9(5,6)	TRP, KYN, XA	Serum	UHPLC -MS/MS	5	11	Low TRP, KYN, XA


10	Gonzalez- Sanchez, Jimenez et al. 2020	Spain	AD	НС	20,41 (7/13), (19/22)	23 (15/8)	43,64 (22/21), (34/30)	71,9(8,1)	64,7(10,8)	TRP, KA	Plasma and CSF	ELISA	7,5	12,5	High c(TRP, KA) Low p(TRP) High p(KA)
17	van der Velpen, Teav et al. 2019	Switzerland	AD	НС	40 (16/24)	34 (11/23)	74 (27/47)	74.8(6.3)	65.3(6.1)	KA, QA, TRP	Plasma and CSF	LC-MS	6	11	Low TRP, High KA, QA
18	Sorgdrager, Vermeiren et al. 2019	Belgium	AD	НС	33 (15/18)	39 (18/21)	72 (33/39)	73,7(6)	71,3(10,7)	3HK, KYN, KA, QA, TRP, XA	Serum and CSF	UPLC	4	12.5	Low s(TRP, 3HK, XA, QA, KA) High sKYN Low c(3HK,KA,XA,QA) High c(TRP, KYN)
19	Jacobs, Lim et al. 2019	Sweden	AD	НС	20 (9/11)	18 (15/3)	38 (24/14)	77,9(7,5)	73,1(7,9	TRP, KYN, KA, 3HK, 3HA, AA, PA, QA	Serum and CSF	UHPLC	2,5	12,5	Low s(TRP,KA) High c(KYN,3HK,AA,P A,QA)

Table 4: Results of Meta-regression

Variables	No. of Studies	Covariates	1-sided p- value	Z-Value
KYN/TRP		Age	0.043	-1.71
	20	No. of cases	0.027	-1.92
		Sample size	0.018	-2.08
	10	Male gender	0.026	-1.93
	18	Female gender	0.013	-2.20
	13	MMSE	0.031	1.87
	21	Central-Peripheral	0.024	1.98
(KA+KYN)/TRP	10	Male gender	0.043	-1.71
	19	Female gender	0.023	-1.99
	21	No. of cases	0.038	-1.77
	21	Sample size	0.026	-1.93
KA/KYN	17	Male gender 0		1.80
	17	Female gender	0.010	2.30
	21	Central-Peripheral	0.003	-2.67
3HK/KYN	16	Age	0.012	2.23
(KYN+3HK+XA+QA+PA)/ (KA+AA)	20	Central-Peripheral	0.001	3.10
(KA+AA)	17	Male gender	0.043	-1.71
	17	Female gender	0.037	-1.78
avv.	11	Age	0.014	2.18
3НК	11	Central-Peripheral	0.009	2.34
KA	14	Central-Peripheral	0.007	-2.45
TRP	17	Age	0.003	2.71
	10	No. of cases	0.009	2.35
	18	Sample size	0.007	2.41
	16	Male gender	0.018	2.08
	16	Female gender	0.022	2

KYN	15	Male gender	0.023	-1.98	
		Female gender	0.004	-2.60	






Almulla et al, 2022


ESF, Figure 1: The forest plot of kynurenine (KYN)+Kynurenic acid (KA)/ Tryptophan (TRP) ratio in patients with Alzheimer disease (AD) compared to healthy control reflecting IDO enzyme activity.

KA/KYN



Almulla et al, 2022


ESF, Figure 2: The forest plot of Kynurenic acid (KA)/kynurenine (KYN)ratio in patients with Alzheimer disease (AD) compared to healthy control reflecting KAT enzyme activity.



Almulla et al, 2022


ESF, Figure 3: The forest plot of Kynurenic acid (KA)/kynurenine (KYN)+ Tryptophan (TRP) ratio in patients with Alzheimer disease (AD) compared to healthy control reflecting KAT enzyme activity.

3HK/KYN



Almulla et al, 2022


ESF, Figure 4: The forest plot of 3-Hydroxykynurenine/kynurenine (KYN) ratio in patients with Alzheimer disease (AD) compared to healthy control reflecting KMO enzyme activity.



Almulla et al, 2022

ESF, Figure 5: The forest plot of kynurenine (KYN)+3Hydroxykynurenine (3HK)+Quinolinic acid(QA)+Xanthurenic acid (XA)+Picolinic acid (PA)/Kynurenine acid (KA)+Anthranilic acid(AA) ratio in patients with Alzheimer disease (AD) compared to healthy control reflecting neurotoxic over neuroprotective TRYCATs.

KYN




Control AD Patients

Almulla et al, 2022

ESF, Figure 6: The forest plot of kynurenine (KYN) in patients with Alzheimer disease (AD) compared to healthy control.


KA



Almulla et al, 2022

ESF, Figure 7: The forest plot of kynurenic acid (KA) in patients with Alzheimer disease (AD) compared to healthy control.

3HK




Control AD Patients

Almulla et al, 2022

ESF, Figure 8: The forest plot of 3-Hydroxykynurenine (3HK) in patients with Alzheimer disease (AD) compared to healthy control.

XA



Control AD Patients

Almulla et al, 2022

ESF, Figure 9: The forest plot of xanthurenic acid (XA) in patients with Alzheimer disease (AD) compared to healthy control.

Abbreviations:

AD: Alzheimer disease

TRP: Tryptophan

KYN: Kynurenine

KA: Kynurenic acid

3HK: 3-Hydroxykynurenine

AA: Anthranilic acid

3HA: 3-Hydroxyanthranilic acid

XA: Xanthurenic acid

QA: Quinolinic acid

PA: Picolinic acid

IDO: Indoleamine 2,3 dioxygenase

TDO: Tryptophan 2,3 dioxygenase

KAT: Kynurenine aminotransferase

KMO: Kynurenine 3-monooxygenase

KYNU: Kynureninase

NAD+: Nicotinamide adenine dinucleotide

TRYCATs: Tryptophan Catabolites

TRYCAT pathway: Tryptophan catabolite pathway

KP: Kynurenine pathway

SMD: Standardized mean difference

CI: Confidence intervals

CSF: Cerebrospinal fluid

LC-MS: Liquid chromatography-mass spectrometry

LC-MS/MS: Liquid chromatography with two mass spectrometry

UHPLC-MS: Ultra-high-performance liquid-chromatography- mass spectrometry

NMDA: N-methyl-D-aspartate

Aβ: amyloid-beta

IL-6: Interleukin-6

TNF-α: Tumor necrosis factor

IL-1ra: IL-1 receptor antagonist

IL-10: Interleukin-6

IL-1β: Interleukin-1beta

IFN-γ: Interferon-gamma

O&NS: Oxidative and nitrosative stress

ROS: Reactive oxygen species

LPS: Lipopolysaccharides

VGLUT: Reducing vesicular glutamate transport

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

MOOSE: Reviews and Interventions and Meta-Analyses of Observational Studies in Epidemiology

ESF: Electronic supplementary file

SD: Standard deviation

SEM: Standard error

ICS: Immune confounder scales

CNS: Central nervous system

NADPH: Nicotinamide adenine dinucleotide phosphate